Verici Dx - Immunodiagnostics for kidney transplants

Verici Dx is an immunodiagnostics company focused on the development of tests for the kidney transplantation market. These tests use next-generation RNA sequencing to create a defined risk profile for transplant patients, allowing the tailoring of immunosuppressive therapy and identification of rejection events. The company has two lead products, the pre-transplant test Clarava, and a post-transplant early prognostic called Tuteva, both of which are in clinical validation trials. A third product, Protega, is under development for the prediction of fibrosis and long-term graft failure. Data for these trials are expected to be reported in Q122, with plans in place to commercialise both products quickly afterwards.

Den vollständigen Artikel lesen ...